CoChat
Sign Up
Cited by 142Nanoplatforms for cancer theranosticsMolecular Sensors and Ion DetectionOptical Imaging and Spectroscopy Techniques

AND-gate contrast agents for enhanced fluorescence-guided surgery

Open access
Widen, John C., Tholen, Martina, Yim, Joshua J., Antaris, Alexander, Casey, Kerriann M., Rogalla, Stephan, Klaassen, Alwin, Sorger, Jonathan +1 more·2020·Nature Biomedical Engineering
DOI 10.1038/s41551-020-00616-6PMC PMC7969380
Open this paper in CoChat — free account

Abstract

Surgical resection of tumours requires precisely locating and defining the margins between lesions and normal tissue. However, this is made difficult by irregular margin borders. Although molecularly targeted optical contrast agents can be used to define tumour margins during surgery in real time, the selectivity of the contrast agents is often limited by the target being expressed in both healthy and tumour tissues. Here, we show that AND-gate optical imaging probes that require the processing of two substrates by multiple tumour-specific enzymes produce a fluorescent signal with significantly improved specificity and sensitivity to tumour tissue. We evaluated the performance of the probes in mouse models of mammary tumours and of metastatic lung cancer, as well as during fluorescence-guided robotic surgery. Imaging probes that rely on multivariate activation to selectively target complex patterns of enzymatic activity should be useful in disease detection, treatment and monitoring.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41551-020-00616-6

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 45

  1. [1]Tringale KR, Pang J & Nguyen QT Image-guided surgery in cancer: A strategy to reduce incidence of positive surgical margins. Wiley Interdiscip Rev Syst Biol Med 10, e1412 (2018). 29474004
  2. [2]Orosco RK Positive Surgical Margins in the 10 Most Common Solid Cancers. Sci Rep 8, 5686 (2018). 29632347 PMC5890246
  3. [3]Yossepowitch O Positive surgical margins after radical prostatectomy: a systematic review and contemporary update. Eur Urol 65, 303– 313 (2014). 23932439
  4. [4]Winter JM 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 10, 1199– 1210; discussion 1210–1191 (2006). 17114007
  5. [5]McGirt MJ Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 63, 700– 707; author reply 707–708 (2008). 18981880
  6. [6]Brouwer de Koning SG, Vrancken Peeters M, Jozwiak K, Bhairosing PA & Ruers TJM Tumor Resection Margin Definitions in Breast-Conserving Surgery: Systematic Review and Meta-analysis of the Current Literature. Clin Breast Cancer (2018). 29731404
  7. [7]Morrow M Trends in Reoperation After Initial Lumpectomy for Breast Cancer: Addressing Overtreatment in Surgical Management. JAMA Oncol (2017). PMC5710510 28586788
  8. [8]Weissleder R & Pittet MJ Imaging in the era of molecular oncology. Nature 452, 580– 589 (2008). 18385732 PMC2708079
  9. [9]Valdes PA, Roberts DW, Lu FK & Golby A Optical technologies for intraoperative neurosurgical guidance. Neurosurg Focus 40, E8 (2016). PMC4860344 26926066
  10. [11]Thill M MarginProbe: intraoperative margin assessment during breast conserving surgery by using radiofrequency spectroscopy. Expert Rev Med Devices 10, 301– 315 (2013). 23668703
  11. [12]Garland M, Yim JJ & Bogyo M A Bright Future for Precision Medicine: Advances in Fluorescent Chemical Probe Design and Their Clinical Application. Cell Chem Biol 23, 122– 136 (2016). 26933740 PMC4779185
  12. [13]Gossedge G, Vallance A & Jayne D Diverse applications for near infra-red intraoperative imaging. Colorectal Dis 17 Suppl 3, 7– 11 (2015). 26394736
  13. [14]Ferraro N The role of 5-aminolevulinic acid in brain tumor surgery: a systematic review. Neurosurg Rev 39, 545– 555 (2016). 26815631
  14. [15]Nguyen QT & Tsien RY Fluorescence-guided surgery with live molecular navigation--a new cutting edge. Nat Rev Cancer 13, 653– 662 (2013). 23924645 PMC4427343
  15. [16]Weissleder R, Tung CH, Mahmood U & Bogdanov A Jr. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 17, 375– 378 (1999). 10207887
  16. [18]Whitney M Ratiometric activatable cell-penetrating peptides provide rapid in vivo readout of thrombin activation. Angew Chem Int Ed Engl 52, 325– 330 (2013). 23080482 PMC3694763
  17. [19]Sakabe M Rational design of highly sensitive fluorescence probes for protease and glycosidase based on precisely controlled spirocyclization. J Am Chem Soc 135, 409– 414 (2013). 23205758
  18. [20]Ofori LO Design of Protease Activated Optical Contrast Agents That Exploit a Latent Lysosomotropic Effect for Use in Fluorescence-Guided Surgery. ACS Chem Biol 10, 1977– 1988 (2015). 26039341 PMC4577961
  19. [21]Egeblad M & Werb Z New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2, 161– 174 (2002). 11990853
  20. [23]Mohamed MM & Sloane BF Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 6, 764– 775 (2006). 16990854
  21. [24]Aggarwal N & Sloane BF Cathepsin B: multiple roles in cancer. Proteomics Clin Appl 8, 427– 437 (2014). 24677670 PMC4205946
  22. [25]Yim JJ, Tholen M, Klaassen A, Sorger J & Bogyo M Optimization of a Protease Activated Probe for Optical Surgical Navigation. Mol Pharm 15, 750– 758 (2018). 29172524
  23. [26]Erbas-Cakmak S Molecular logic gates: the past, present and future. Chem Soc Rev 47, 2228– 2248 (2018). 29493684
  24. [27]Stennicke HR, Renatus M, Meldal M & Salvesen GS Internally quenched fluorescent peptide substrates disclose the subsite preferences of human caspases 1, 3, 6, 7 and 8. Biochem J 350 Pt 2, 563– 568 (2000). 10947972 PMC1221285
  25. [28]Blum G Dynamic imaging of protease activity with fluorescently quenched activity-based probes. Nature chemical biology 1, 203– 209 (2005). 16408036
  26. [30]Loser R & Pietzsch J Cysteine cathepsins: their role in tumor progression and recent trends in the development of imaging probes. Front Chem 3, 37 (2015). 26157794 PMC4477214
  27. [31]Olson OC & Joyce JA Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat Rev Cancer 15, 712– 729 (2015). 26597527
  28. [33]Edgington-Mitchell LE & Bogyo M Detection of Active Caspases During Apoptosis Using Fluorescent Activity-Based Probes. Methods Mol Biol 1419, 27– 39 (2016). 27108429 PMC6091214
  29. [34]Ye D Bioorthogonal cyclization-mediated in situ self-assembly of small-molecule probes for imaging caspase activity in vivo. Nat Chem 6, 519– 526 (2014). 24848238 PMC4031611
  30. [35]Luciano MP A Nonaggregating Heptamethine Cyanine for Building Brighter Labeled Biomolecules. ACS Chem Biol 14, 934– 940 (2019). 31030512 PMC6528163
  31. [36]Busek P, Mateu R, Zubal M, Kotackova L & Sedo A Targeting fibroblast activation protein in cancer - Prospects and caveats. Frontiers in bioscience 23, 1933– 1968 (2018). 29772538
  32. [37]Pure E & Blomberg R Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene 37, 4343– 4357 (2018). 29720723 PMC6092565
  33. [38]Edosada CY Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity. Febs Lett 580, 1581– 1586 (2006). 16480718
  34. [39]Bainbridge TW Selective Homogeneous Assay for Circulating Endopeptidase Fibroblast Activation Protein (FAP). Sci Rep-Uk 7 (2017). PMC5624913 28970566
  35. [40]Zhang HE Identification of Novel Natural Substrates of Fibroblast Activation Protein-alpha by Differential Degradomics and Proteomics. Mol Cell Proteomics 18, 65– 85 (2019). 30257879 PMC6317473
  36. [41]Hua X, Yu L, Huang X, Liao Z & Xian Q Expression and role of fibroblast activation protein-alpha in microinvasive breast carcinoma. Diagnostic pathology 6, 111 (2011). 22067528 PMC3228672
  37. [42]Zi F Fibroblast activation protein alpha in tumor microenvironment: recent progression and implications (review). Molecular medicine reports 11, 3203– 3211 (2015). 25593080 PMC4368076
  38. [43]Fang J A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice. International journal of cancer 138, 1013– 1023 (2016). 26334777 PMC4715643
  39. [44]Winslow MM Suppression of lung adenocarcinoma progression by Nkx2–1. Nature 473, 101– 104 (2011). 21471965 PMC3088778
  40. [45]DuPage M Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer cell 19, 72– 85 (2011). 21251614 PMC3069809
  41. [46]Vickers CJ, Gonzalez-Paez GE & Wolan DW Discovery of a highly selective caspase-3 substrate for imaging live cells. ACS Chem Biol 9, 2199– 2203 (2014). 25133295
  42. [47]Julien O Quantitative MS-based enzymology of caspases reveals distinct protein substrate specificities, hierarchies, and cellular roles. P Natl Acad Sci USA 113, E2001– E2010 (2016). PMC4833263 27006500
  43. [48]Jaattela M Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene 23, 2746– 2756 (2004). 15077138
  44. [49]Labi V & Erlacher M How cell death shapes cancer. Cell death & disease 6, e1675 (2015). 25741600 PMC4385913
  45. [50]Verdoes M Improved quenched fluorescent probe for imaging of cysteine cathepsin activity. J Am Chem Soc 135, 14726– 14730 (2013). 23971698 PMC3826460

Cited by

Sorted by citations

Authors
Widen, J. C., Tholen, M., Yim, J. J., Antaris, A., Casey, K. M., Rogalla, S., Klaassen, A., Sorger, J., & Bogyo, M.
Affiliations
  • Stanford Medicine (US)
  • Intuitive Surgical (United States) (US)
Corresponding author
Bogyo, Matthew
ORCID
Venue
Nature Biomedical Engineering
Publisher
Springer Science and Business Media LLC
Published
2020-09-28
Volume
5
Issue
3
Pages
264-277
ISSN
2157-846X (ISSN-L)
DOI
10.1038/s41551-020-00616-6
PMC
PMC7969380
OpenAlex
W3089876537
Cited by
142
References
5
Citations by year
2026: 15 · 2025: 23 · 2024: 23 · 2023: 27 · 2022: 28 · 2021: 26
FWCI
6.36
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Biomedical Engineering (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • American Cancer Society (PF-19-105-01-CCE)
  • National Science Foundation (DGE-114747)
  • U.S. Department of Health & Human Services | National Institutes of Health (R01 EB026285)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Physical Sciences › Chemistry › Spectroscopy › Molecular Sensors and Ion Detection
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Optical Imaging and Spectroscopy Techniques
Keywords
optical contrast agents, fluorescence-guided surgery, tumour margin delineation, imaging agents, mammary tumors, metastatic lung cancer, robotic surgery, metastasis detection
MeSH terms
RAW 264.7 Cells, Animals, Cell Line, Contrast Media, Disease Models, Animal, Female, Fluorescence, Fluorescent Dyes, Lung Neoplasms, Male, Mice, Inbred BALB C, Mammary Neoplasms, Animal, Surgery, Computer-Assisted, Mice, Optical Imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review